Gilead sues US govt for breach of contract over antiviral patents
29-04-2020
World’s scientists working on nearly 80 COVID-19 vaccines
21-04-2020
Canada authorises compulsory licences for COVID-19 shortfalls
27-03-2020
siam.pukkato / Shutterstock.com
Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.
In a time of crisis, access to appropriate pharmaceuticals is of paramount importance. At present there are six UK centres attempting to find an antiviral treatment for the COVID-19 virus.
There are many more other drug interventions being sought around the world to stop the rampage of the virus. The World Health Organization (WHO) lists at least 60 such projects.
Access to patented pharmaceutical subject matter is denied by the ownership of a patent.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
COVID-19, patents, UK, US, Gilead, remdesivir, the world health organization, Wuhan Institute of Technology, Donald Trump, coronavirus, pandemic
